Depomed (DEPO) Tops Q4 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
RBC Reiterates Sector Perform Rating and $22 PT on Depomed (DEPO) Following 4Q Results, Ahead of 2/23 RBC Healthcare Conference
February 22, 2017 7:42 AM ESTRBC Capital Markets analyst Randall Stanicky reiterates Sector Perform rating and $22 price target on Depomed Inc. (NASDAQ: DEPO), suggesting the strategic outlook remains the focus, as the company reported 2016 fourth quarter revenue and EPS slightly above consensus. RBC Capital Markets will be hosting Depomed at the RBC Healthcare Conference on Thursday,... More
